Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis

References

• World Health Organisation. Global tuberculosis report 2021; 2021.
   Google Scholar
• World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 3: Diagnosis–Rapid Diagnostics for Tuberculosis Detection. World Health Organization; 2021.
   Google Scholar
• Bulterys MA, Wagner B, Redard-Jacot M, et al. Point-of-care urine LAM tests for tuberculosis diagnosis: a status update. J Clin Med. 2020;9(1):111. doi:10.3390/jcm9010111
   Web of Science ®Google Scholar
• García-Basteiro AL, DiNardo A, Saavedra B, et al. Point of care diagnostics for tuberculosis. Pulmonology. 2018;24(2):73–85. doi:10.1016/j.rppnen.2017.12.002
   Web of Science ®Google Scholar
• Dheda K, Ruhwald M, Theron G, Peter J, Yam WC. Point‐of‐care diagnosis of tuberculosis: past, present and future. Respirology. 2013;18(2):217–232. doi:10.1111/resp.12022
   PubMed Web of Science ®Google Scholar
• Branigan D. AN ACTIVIST’S. GUIDE to “Tuberculosis Diagnostic Tools”. New York, NY, USA: Treatment Action Group; 2020.
   Google Scholar
• Schito M, Peter TF, Cavanaugh S, et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis. 2012;205(suppl_2):S169–S180. doi:10.1093/infdis/jis044
   Web of Science ®Google Scholar
• Ryu YJ. Diagnosis of pulmonary tuberculosis: recent advances and diagnostic algorithms. Tuberc Respir Dis. 2015;78(2):64–71. doi:10.4046/trd.2015.78.2.64
   PubMed Web of Science ®Google Scholar
• Harries A. Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet. 1990;335:387–390. doi:10.1016/0140-6736(90)90216-R
   PubMed Web of Science ®Google Scholar
• Peter JG, Theron G, Muchinga TE, Govender U, Dheda K, Goletti D. The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS One. 2012;7(7):e39966. doi:10.1371/journal.pone.0039966
   Web of Science ®Google Scholar
• Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012;40(5):1211–1220. doi:10.1183/09031936.00201711
   PubMed Web of Science ®Google Scholar
• Paris L, Magni R, Zaidi F, et al. Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity. Sci Transl Med. 2017;9(420). doi:10.1126/scitranslmed.aal2807
   Web of Science ®Google Scholar
• Cannas A, Goletti D, Girardi E, et al. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2008;12(2):146–151.
   Web of Science ®Google Scholar
• Oreskovic A, Panpradist N, Marangu D, et al. Diagnosing pulmonary tuberculosis by using sequence-specific purification of urine cell-free DNA. J Clin Microbiol. 2021;59(8):e0007421. doi:10.1128/JCM.00074-21
   PubMed Web of Science ®Google Scholar
• Atherton RR, Cresswell FV, Ellis J, et al. Detection of Mycobacterium tuberculosis in urine by Xpert MTB/RIF Ultra: a useful adjunctive diagnostic tool in HIV-associated tuberculosis. Int J Infect Dis. 2018;75:92–94. doi:10.1016/j.ijid.2018.07.007
   PubMed Web of Science ®Google Scholar
• Horváth I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26(3):523–548. doi:10.1183/09031936.05.00029705
   PubMed Web of Science ®Google Scholar
• Chen D, Bryden NA, Bryden WA, et al. Non-volatile organic compounds in exhaled breath particles correspond to active tuberculosis. Sci Rep. 2022;12(1):7919. doi:10.1038/s41598-022-12018-6
   Web of Science ®Google Scholar
• Chen D, Bryden WA, Wood R. Detection of tuberculosis by the analysis of exhaled breath particles with high-resolution mass spectrometry. Sci Rep. 2020;10(1):7647. doi:10.1038/s41598-020-64637-6
   Web of Science ®Google Scholar
• Zijenah LS. The world health organization recommended TB diagnostic tools. Tuberculosis. 2018;2:71–90.
   Google Scholar
• Hobby GL, Holman AP, Iseman MD, Jones JM. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 1973;4(2):94–104. doi:10.1128/AAC.4.2.94
   PubMed Web of Science ®Google Scholar
• Cudahy P, Shenoi SV. Diagnostics for pulmonary tuberculosis. Postgrad Med J. 2016;92(1086):187–193. doi:10.1136/postgradmedj-2015-133278
   PubMed Web of Science ®Google Scholar
• Harries AD, Kumar A. Challenges and progress with diagnosing pulmonary tuberculosis in low-and middle-income countries. Diagnostics. 2018;8(4):78. doi:10.3390/diagnostics8040078
   Web of Science ®Google Scholar
• Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol. 2004;42(5):2321–2325. doi:10.1128/JCM.42.5.2321-2325.2004
   PubMed Web of Science ®Google Scholar
• Ardito F, Posteraro B, Sanguinetti M, Zanetti S, Fadda G. Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2001;39(12):4440–4444. doi:10.1128/JCM.39.12.4440-4444.2001
   Web of Science ®Google Scholar
• Schön T, Miotto P, Köser CU, Viveiros M, Böttger E, Cambau E. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin Microbiol Infect. 2017;23(3):154–160. doi:10.1016/j.cmi.2016.10.022
   PubMed Web of Science ®Google Scholar
• Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104(6):901–912. doi:10.1016/S0092-8674(01)00286-0
   PubMed Web of Science ®Google Scholar
• Steingart KR, Sohn H, Schiller I, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2013;(1). doi:10.1002/14651858.CD009593.pub2
   Web of Science ®Google Scholar
• Wang S, Zhao B, Song Y, et al. Molecular characterization of the rpoB gene mutations of Mycobacterium tuberculosis isolated from China. J Tuberc Res. 2013;01(01):1–8. doi:10.4236/jtr.2013.11001
   Google Scholar
• Bunsow E, Ruiz-Serrano MJ, Roa PL, Kestler M, Viedma DG, Bouza E. Evaluation of GeneXpert MTB/RIF for the detection of Mycobacterium tuberculosis and resistance to rifampin in clinical specimens. J Infect. 2014;68(4):338–343. doi:10.1016/j.jinf.2013.11.012
   PubMed Web of Science ®Google Scholar
• Ochang EA, Udoh UA, Emanghe UE, et al. Evaluation of rifampicin resistance and 81-bp rifampicin resistant determinant region of rpoB gene mutations of Mycobacterium tuberculosis detected with XpertMTB/Rif in Cross River State, Nigeria. Int J Mycobacteriol. 2016;5(5):145. doi:10.1016/j.ijmyco.2016.09.007
   Google Scholar
• Ramasamy P, Sounderrajan V, Harshavardhan S, Harshavardhan S. Current perceptions on advanced molecular diagnostics for drug-resistant Mycobacterium tuberculosis. Biomed Pharmacol J. 2021;14(3):1249–1257. doi:10.13005/bpj/2226
   Google Scholar
• Nguyen TNA, Berre A-L, Bañuls A-L, Nguyen TVA. Molecular diagnosis of drug-resistant tuberculosis; a literature review. Front Microbiol. 2019;10:794. doi:10.3389/fmicb.2019.00794
   PubMed Web of Science ®Google Scholar
• Lee H, Seong M, Park S, et al. Diagnostic accuracy of Xpert® MTB/RIF on bronchoscopy specimens in patients with suspected pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013;17(7):917–921. doi:10.5588/ijtld.12.0885
   Web of Science ®Google Scholar
• Scott LE, Beylis N, Nicol M, et al. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. J Clin Microbiol. 2014;52(6):1818–1823. doi:10.1128/JCM.03553-13
   PubMed Web of Science ®Google Scholar
• Sharma SK, Kohli M, Yadav RN, et al. Evaluating the diagnostic accuracy of Xpert MTB/RIF assay in pulmonary tuberculosis. PLoS One. 2015;10(10):e0141011. doi:10.1371/journal.pone.0141011
   PubMed Web of Science ®Google Scholar
• Allahyartorkaman M, Mirsaeidi M, Hamzehloo G, Amini S, Zakiloo M, Nasiri MJ. Low diagnostic accuracy of Xpert MTB/RIF assay for extrapulmonary tuberculosis: a multicenter surveillance. Sci Rep. 2019;9(1):1–6. doi:10.1038/s41598-019-55112-y
   PubMed Web of Science ®Google Scholar
• Bahr NC, Nuwagira E, Evans EE, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis. 2018;18(1):68–75. doi:10.1016/S1473-3099(17)30474-7
   PubMed Web of Science ®Google Scholar
• Mekkaoui L, Hallin M, Mouchet F, et al. Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra-pulmonary tuberculosis, one year of use in a multi-centric hospital laboratory in Brussels, Belgium. PLoS One. 2021;16(4):e0249734. doi:10.1371/journal.pone.0249734
   PubMed Web of Science ®Google Scholar
• Nicol MP, Workman L, Prins M, et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pulmonary tuberculosis in children. Pediatr Infect Dis J. 2018;37(10):e261–e3. doi:10.1097/INF.0000000000001960
   PubMed Web of Science ®Google Scholar
• Moure R, Martín R, Alcaide F. Effectiveness of an integrated real-time PCR method for detection of the Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples in an area of low tuberculosis prevalence. J Clin Microbiol. 2012;50(2):513–515. doi:10.1128/JCM.06467-11
   Web of Science ®Google Scholar
• Rasheed W, Rao NA, Adel H, Baig MS, Adil SO. Diagnostic accuracy of Xpert MTB/RIF in sputum smear-negative pulmonary tuberculosis. Cureus. 2019;11(8):e5391. doi:10.7759/cureus.5391
   Web of Science ®Google Scholar
• Khadka P, Thapaliya J, Basnet RB, Ghimire GR, Amatya J, Rijal BP. Diagnosis of tuberculosis from smear-negative presumptive TB cases using Xpert MTB/Rif assay: a cross-sectional study from Nepal. BMC Infect Dis. 2019;19(1):1090. doi:10.1186/s12879-019-4728-2
   Web of Science ®Google Scholar
• Sanchez-Padilla E, Merker M, Beckert P, et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med. 2015;372(12):1181–1182. doi:10.1056/NEJMc1413930
   PubMed Web of Science ®Google Scholar
• Manson AL, Cohen KA, Abeel T, et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat Genet. 2017;49(3):395–402. doi:10.1038/ng.3767
   PubMed Web of Science ®Google Scholar
• Clouse K, Page-Shipp L, Dansey H, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. South Afr Med J. 2012;102(10):805–807. doi:10.7196/SAMJ.5851
   PubMed Web of Science ®Google Scholar
• Hanrahan C, Clouse K, Bassett J, et al. The patient impact of point-of-care vs. laboratory placement of Xpert® MTB/RIF. Int J Tuberc Lung Dis. 2015;19(7):811–816. doi:10.5588/ijtld.15.0013
   Web of Science ®Google Scholar
• Hanrahan CF, Selibas K, Deery CB, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013;8(6):e65421. doi:10.1371/journal.pone.0065421
   Web of Science ®Google Scholar
• Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383(9915):424–435. doi:10.1016/S0140-6736(13)62073-5
   PubMed Web of Science ®Google Scholar
• Detjen AK, DiNardo AR, Leyden J, et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(6):451–461. doi:10.1016/S2213-2600(15)00095-8
   PubMed Web of Science ®Google Scholar
• Marcy O, Ung V, Goyet S, et al. Performance of Xpert MTB/RIF and alternative specimen collection methods for the diagnosis of tuberculosis in HIV-infected children. Clin Infect Dis. 2016;62(9):1161–1168. doi:10.1093/cid/ciw036
   Web of Science ®Google Scholar
• Schnippel K, Meyer‐Rath G, Long L, et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory‐vs. clinic‐based roll‐out in South Africa. Trop Med Int Health. 2012;17(9):1142–1151. doi:10.1111/j.1365-3156.2012.03028.x
   PubMed Web of Science ®Google Scholar
• Theron G. Point‐of‐care technologies for the diagnosis of active tuberculosis. Mol Microbiol. 2016;556–579. doi:10.1128/9781555819071.ch40
   Google Scholar
• Churchyard GJ, Stevens WS, Mametja LD, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Global Health. 2015;3(8):e450–e457. doi:10.1016/S2214-109X(15)00100-X
   PubMed Web of Science ®Google Scholar
• Cox HS, Mbhele S, Mohess N, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med. 2014;11(11):e1001760. doi:10.1371/journal.pmed.1001760
   Web of Science ®Google Scholar
• Theron G, Peter J, Calligaro G, et al. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Sci Rep. 2014;4(1):1–10.
   Google Scholar
• Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis. 2014;14(6):527–532. doi:10.1016/S1473-3099(13)70360-8
   PubMed Web of Science ®Google Scholar
• Chakravorty S, Simmons AM, Rowneki M, et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio. 2017;8(4):e00812–e00817. doi:10.1128/mBio.00812-17
   PubMed Web of Science ®Google Scholar
• Perez-Risco D, Rodriguez-Temporal D, Valledor-Sanchez I, Alcaide F, Land GA. Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. J Clin Microbiol. 2018;56(9):e00659–18. doi:10.1128/JCM.00659-18
   PubMed Web of Science ®Google Scholar
• Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76–84. doi:10.1016/S1473-3099(17)30691-6
   PubMed Web of Science ®Google Scholar
• Kohli M, Schiller I, Dendukuri N, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2021;(1). doi:10.1002/14651858.CD012768.pub3
   Web of Science ®Google Scholar
• Sabi I, Rachow A, Mapamba D, et al. Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study. J Infect. 2018;77(4):321–327. doi:10.1016/j.jinf.2018.07.002
   PubMed Web of Science ®Google Scholar
• Wang G, Wang S, Jiang G, et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. J Infect. 2019;78(4):311–316. doi:10.1016/j.jinf.2019.02.010
   PubMed Web of Science ®Google Scholar
• Mishra H, Reeve BW, Palmer Z, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. Lancet Respir Med. 2020;8(4):368–382. doi:10.1016/S2213-2600(19)30370-4
   PubMed Web of Science ®Google Scholar
• Cepheid. Xpert MTB-XDR English Package Insert 302–351. 4 Rev A; 2020.
   Google Scholar
• Cao Y, Parmar H, Gaur RL, et al. Xpert MTB/XDR: a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from Mycobacterium tuberculosis-positive sputum. J Clin Microbiol. 2021;59(3):e02314–e02320. doi:10.1128/JCM.02314-20
   PubMed Web of Science ®Google Scholar
• Georghiou SB, Penn-Nicholson A, de Vos M, et al. Analytical performance of the Xpert MTB/XDR® assay for tuberculosis and expanded resistance detection. Diagn Microbiol Infect Dis. 2021;101(1):115397. doi:10.1016/j.diagmicrobio.2021.115397
   Web of Science ®Google Scholar
• Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med. 2017;377(11):1043–1054. doi:10.1056/NEJMoa1614915
   PubMed Web of Science ®Google Scholar
• Penn-Nicholson A, Georghiou SB, Ciobanu N, et al. Clinical evaluation of the Xpert MTB/XDR assay for rapid detection of isoniazid, fluoroquinolone, ethionamide and second-line drug resistance: a cross-sectional multicentre diagnostic accuracy study. medRxiv. 2021. doi:10.1101/2021.05.06.21256505
   Google Scholar
• Bainomugisa A, Gilpin C, Coulter C, Marais BJ. New xpert MTB/XDR: added value and future in the field. Eur Respiratory Soc. 2020;56(5):2003616. doi:10.1183/13993003.03616-2020
   Web of Science ®Google Scholar
• Truenat. MTB-RIF Dx English Package Insert; 2018.
   Google Scholar
• Penn-Nicholson A, Gomathi SN, Ugarte-Gil C, et al. A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays. Eur Respir J. 2021;58(5):2100526. doi:10.1183/13993003.00526-2021
   PubMed Web of Science ®Google Scholar
• Kohli M, MacLean E, Pai M, Denkinger CM. Web Annex 4.8. Moderate complexity automated NAATs: diagnostic accuracy for TB detection and detection of resistance to rifampicin and isoniazid. A systematic review and meta-analysis. WHO consolidated guidelines on tuberculosis Module 3: diagnosis–rapid diagnostics for tuberculosis detection; 2021:181.
   Google Scholar
• Araya BT, Ali KE, Geleta DA, Tekele SG, Tulu KD, Quinn F. Performance of the Abbott RealTime MTB and RIF/INH resistance assays for the detection of Mycobacterium tuberculosis and resistance markers in sputum specimens. PLoS One. 2021;16(5):e0251602. doi:10.1371/journal.pone.0251602
   Web of Science ®Google Scholar
• David A, Singh L, Da Silva P, Scott L, Stevens W. The performance of the Abbott real time MTB RIF/INH compared to the MTBDRplus V2 for the identification of MDR-TB among isolates. Infect Drug Resist. 2020;13:3301. doi:10.2147/IDR.S247524
   Web of Science ®Google Scholar
• Kostera J, Leckie G, Abravaya K, Wang H. Performance of the Abbott RealTime MTB RIF/INH resistance assay when used to test Mycobacterium tuberculosis specimens from Bangladesh. Infect Drug Resist. 2018;11:695. doi:10.2147/IDR.S158953
   PubMed Web of Science ®Google Scholar
• Scott L, David A, Noble L, et al. Performance of the Abbott RealTi me MTB and MTB RIF/INH assays in a setting of high tuberculosis and HIV coinfection in South Africa. J Clin Microbiol. 2017;55(8):2491–2501. doi:10.1128/JCM.00289-17
   PubMed Web of Science ®Google Scholar
• Wang M-G, Xue M, Wu S-Q, et al. Abbott RealTime MTB and MTB RIF/INH assays for the diagnosis of tuberculosis and rifampicin/isoniazid resistance. Infect Genet Evol. 2019;71:54–59. doi:10.1016/j.meegid.2019.03.012
   Web of Science ®Google Scholar
• Dickinson B. BD MAX™ multi drug resistant tuberculosis (MDR-TB) assay. Pack insert; 2020.
   Google Scholar
• Sağiroğlu P, Atalay MA. Evaluation of the performance of the BD MAX MDR-TB test in the diagnosis of Mycobacterium tuberculosis complex in extrapulmonary and pulmonary samples. Expert Rev Mol Diagn. 2021;21(12):1361–1367. doi:10.1080/14737159.2021.1997594
   PubMed Web of Science ®Google Scholar
• Shah M, Paradis S, Betz J, et al. Multicenter study of the accuracy of the BD MAX™ MDR-TB assay for detection of Mycobacterium tuberculosis complex and mutations associated with resistance to rifampin and isoniazid. Clin Infect Dis. 2019;71(5):1161–1167.
   Web of Science ®Google Scholar
• Ciesielczuk H, Kouvas N, North N, Buchanan R, Tiberi S. Evaluation of the BD MAX™ MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB. Eur J Clin Microbiol Infect Dis. 2020;39(7):1321–1327. doi:10.1007/s10096-020-03847-2
   Web of Science ®Google Scholar
• Beutler M, Plesnik S, Mihalic M, et al. A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB/Rif Ultra and FluoroType MTB. PLoS One. 2020;15(1):e0227215. doi:10.1371/journal.pone.0227215
   Web of Science ®Google Scholar
• Hofmann-Thiel S, Plesnik S, Mihalic M, et al. Clinical evaluation of BD MAX MDR-TB assay for direct detection of Mycobacterium tuberculosis complex and resistance markers. J Mol Diagn. 2020;22(10):1280–1286. doi:10.1016/j.jmoldx.2020.06.013
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, King B, Dorman SE, et al. Multicenter study of the accuracy of the BD MAX MDR-TB assay for detection of Mycobacterium tuberculosis complex and mutations associated with resistance to rifampin and isoniazid. Clin Infect Dis. 2019. doi:10.1093/cid/ciz932
   Web of Science ®Google Scholar
• Nadarajan D, Hillemann D, Kamara R, et al. Evaluation of the Roche cobas MTB and MTB-RIF/INH assays in samples from Germany and Sierra Leone. J Clin Microbiol. 2021;59(5):e02983–20. doi:10.1128/JCM.02983-20
   Web of Science ®Google Scholar
• Scott L, David A, Govender L, et al. Performance of the Roche cobas MTB assay for the molecular diagnosis of pulmonary tuberculosis in a high HIV burden setting. J Mol Diagn. 2020;22(10):1225–1237. doi:10.1016/j.jmoldx.2020.06.018
   Web of Science ®Google Scholar
• de Vos M, Scott L, David A, et al. Comparative analytical evaluation of four centralized platforms for the detection of Mycobacterium tuberculosis complex and resistance to rifampicin and isoniazid. J Clin Microbiol. 2021;59(3):e02168–20. doi:10.1128/JCM.02168-20
   Web of Science ®Google Scholar
• Haasis C, Rupp J, Andres S, et al. Validation of the FluoroType® MTBDR assay using respiratory and lymph node samples. Tuberculosis. 2018;113:76–80. doi:10.1016/j.tube.2018.09.004
   Web of Science ®Google Scholar
• Svensson E, Folkvardsen DB, Rasmussen EM, Lillebaek T. Detection of Mycobacterium tuberculosis complex in pulmonary and extrapulmonary samples with the FluoroType MTBDR assay. Clin Microbiol Infect. 2021;27(10):1514.e1–1514.e4. doi:10.1016/j.cmi.2020.12.020
   Web of Science ®Google Scholar
• Dippenaar A, Derendinger B, Dolby T, et al. Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralised high throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance. Clin Microbiol Infect. 2021;27(9):1351.e1–1351.e4. doi:10.1016/j.cmi.2021.04.022
   Web of Science ®Google Scholar
• de Vos M, Derendinger B, Dolby T, et al. Diagnostic accuracy and utility of FluoroType MTBDR, a new molecular assay for multidrug-resistant tuberculosis. J Clin Microbiol. 2018;56(9):e00531–18. doi:10.1128/JCM.00531-18
   Web of Science ®Google Scholar
• Hillemann D, Haasis C, Andres S, Behn T, Kranzer K, Land GA. Validation of the FluoroType MTBDR assay for detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2018;56(6):e00072–18. doi:10.1128/JCM.00072-18
   Web of Science ®Google Scholar
• MacLean E, Kohli M, Weber SF, et al. Advances in molecular diagnosis of tuberculosis. J Clin Microbiol. 2020;58(10):e01582–19. doi:10.1128/JCM.01582-19
   PubMed Web of Science ®Google Scholar
• Mäkinen J, Marttila HJ, Marjamäki M, Viljanen MK, Soini H. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2006;44(2):350–352. doi:10.1128/JCM.44.2.350-352.2006
   Web of Science ®Google Scholar
• Bang D, Bengård Andersen AS, Thomsen VØ. Rapid genotypic detection of rifampin-and isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimens. J Clin Microbiol. 2006;44(7):2605–2608. doi:10.1128/JCM.00752-06
   Web of Science ®Google Scholar
• Gamboa F, Cardona P, Manterola J, et al. Evaluation of a commercial probe assay for detection of rifampin resistance in Mycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples. Eur J Clin Microbiol Infect Dis. 1998;17(3):189–192. doi:10.1007/BF01691116
   PubMed Web of Science ®Google Scholar
• Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2005;43(8):3699–3703. doi:10.1128/JCM.43.8.3699-3703.2005
   PubMed Web of Science ®Google Scholar
• Tortoli E, Marcelli F. Use of the INNO LiPA Rif. TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility. Eur J Clin Microbiol Infect Dis. 2007;26(1):51–55. doi:10.1007/s10096-006-0240-x
   Web of Science ®Google Scholar
• Bai Y, Wang Y, Shao C, Hao Y, GenoType JY, Chatterji D. MTBDR plus assay for rapid detection of multidrug resistance in Mycobacterium tuberculosis: a meta-analysis. PLoS One. 2016;11(3):e0150321. doi:10.1371/journal.pone.0150321
   Web of Science ®Google Scholar
• Nathavitharana RR, Hillemann D, Schumacher SG, et al. Multicenter noninferiority evaluation of Hain GenoType MTBDR plus version 2 and Nipro NTM+ MDRTB line probe assays for detection of rifampin and isoniazid resistance. J Clin Microbiol. 2016;54(6):1624–1630. doi:10.1128/JCM.00251-16
   Web of Science ®Google Scholar
• Dantas NGT, Suffys PN, Carvalho WDS, et al. Correlation between the BACTEC MGIT 960 culture system with Genotype MTBDRplus and TB-SPRINT in multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. Mem Inst Oswaldo Cruz. 2017;112:769–774. doi:10.1590/0074-02760170062
   Web of Science ®Google Scholar
• Meaza A, Kebede A, Yaregal Z, et al. Evaluation of genotype MTBDR plus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect Dis. 2017;17(1):1–8. doi:10.1186/s12879-017-2389-6
   Web of Science ®Google Scholar
• Dorman SE, Chihota VN, Lewis JJ, et al. Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. J Clin Microbiol. 2012;50(4):1189–1194. doi:10.1128/JCM.05723-11
   Web of Science ®Google Scholar
• Tomasicchio M, Theron G, Pietersen E, et al. The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates. Sci Rep. 2016;6:17850. doi:10.1038/srep17850
   PubMed Web of Science ®Google Scholar
• World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance. World Health Organization; 2016. Report No.: 9241516135.
   Google Scholar
• Javed H, Bakuła Z, Pleń M, et al. Evaluation of genotype MTBDRplus and MTBDRsl assays for rapid detection of drug resistance in extensively drug-resistant Mycobacterium tuberculosis isolates in Pakistan. Front Microbiol. 2018;9:2265. doi:10.3389/fmicb.2018.02265
   Web of Science ®Google Scholar
• Kiet VS, Lan NTN, An DD, et al. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2010;48(8):2934–2939. doi:10.1128/JCM.00201-10
   PubMed Web of Science ®Google Scholar
• Theron G, Peter J, Richardson M, Warren R, Dheda K, Steingart KR. GenoType ® MTBDR sl assay for resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev. 2016;2016(9). doi:10.1002/14651858.CD010705.pub3
   Web of Science ®Google Scholar
• Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J. 2013;42(1):252–271. doi:10.1183/09031936.00157212
   PubMed Web of Science ®Google Scholar
• Parsons LM, Somoskövi Á, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev. 2011;24(2):314–350. doi:10.1128/CMR.00059-10
   PubMed Web of Science ®Google Scholar
• Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet. 2012;379(9829):1902–1913. doi:10.1016/S0140-6736(12)60727-2
   PubMed Web of Science ®Google Scholar
• Matteelli A, Centis R, D’Ambrosio L, Migliori G. Multidrug-resistant tuberculosis today. SciELO Public Health. 2012;90:78.
   Google Scholar
• World Health Organization. Development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease 2017 WHO collaborating centre for the evaluation of new diagnostic technologies. Geneva, Switzerland: World Health Organization; 2017.
   Google Scholar
• Hanrahan CF, Shah M. Economic challenges associated with tuberculosis diagnostic development. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):499–510. doi:10.1586/14737167.2014.914438
   PubMed Web of Science ®Google Scholar
• Goletti D, Petruccioli E, Joosten SA, Ottenhoff TH. Tuberculosis biomarkers: from diagnosis to protection. Infect Dis Rep. 2016;8(2):24–32. doi:10.4081/idr.2016.6568
   Google Scholar
• Lessells RJ, Cooke GS, Newell M-L, Godfrey-Faussett P. Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact. J Infect Dis. 2011;204(suppl_4):S1187–S95. doi:10.1093/infdis/jir412
   Web of Science ®Google Scholar